{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:29:23Z","timestamp":1781148563473,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["AAP 2016-017"],"award-info":[{"award-number":["AAP 2016-017"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40263-020-00774-w","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T06:03:02Z","timestamp":1607148182000},"page":"1267-1274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Prescription Practices of Domperidone in Parkinson\u2019s Disease: A Cross Sectional Study Among French Neurologists"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-1597","authenticated-orcid":false,"given":"Diane","family":"Lastennet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise-Laure","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Denis","family":"Turc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Alfaisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Corvol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"issue":"6","key":"774_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM. Epidemiology of Parkinson\u2019s disease. Lancet Neurol. 2006;5(6):525\u201335.","journal-title":"Lancet Neurol."},{"issue":"9","key":"774_CR2","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/mds.27447","volume":"33","author":"M Wanneveich","year":"2018","unstructured":"Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P. Projections of prevalence, lifetime risk, and life expectancy of Parkinson\u2019s disease (2010\u20132030) in France. Move Disord. 2018;33(9):1449\u201355.","journal-title":"Move Disord."},{"issue":"7844","key":"774_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(73)92729-3","volume":"2","author":"CD Marsden","year":"1973","unstructured":"Marsden CD, Parkes JD, Rees JE. A year\u2019s comparison of treatment of patients with Parkinson\u2019s disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet. 1973;2(7844):1459\u201362.","journal-title":"Lancet"},{"issue":"1","key":"774_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/mds.870130111","volume":"13","author":"O Rascol","year":"1998","unstructured":"Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Move Disord. 1998;13(1):39\u201345.","journal-title":"Move Disord."},{"issue":"2","key":"774_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1212\/WNL.48.2.363","volume":"48","author":"UK Rinne","year":"1997","unstructured":"Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Cabergoline in the treatment of early Parkinson\u2019s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology. 1997;48(2):363\u20138.","journal-title":"Neurology."},{"issue":"8","key":"774_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","volume":"12","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson\u2019s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12(8):747\u201355.","journal-title":"Lancet Neurol."},{"issue":"4","key":"774_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"RL Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272\u20136.","journal-title":"Neurology."},{"issue":"4","key":"774_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1345\/aph.18003","volume":"33","author":"JA Barone","year":"1999","unstructured":"Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429\u201340.","journal-title":"Ann Pharmacother."},{"issue":"8116","key":"774_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S0140-6736(79)91003-1","volume":"1","author":"Y Agid","year":"1979","unstructured":"Agid Y, Pollak P, Bonnet AM, Signoret JL, Lhermitte F. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson\u2019s disease. Lancet. 1979;1(8116):570\u20132.","journal-title":"Lancet"},{"issue":"11","key":"774_CR10","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/mds.21428","volume":"22","author":"KL Schoffer","year":"2007","unstructured":"Schoffer KL, Henderson RD, O\u2019Maley K, O\u2019Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson\u2019s disease. Move Disord. 2007;22(11):1543\u20139.","journal-title":"Move Disord."},{"issue":"8415","key":"774_CR11","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0140-6736(84)90841-9","volume":"2","author":"G Giaccone","year":"1984","unstructured":"Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet. 1984;2(8415):1336\u20137.","journal-title":"Lancet"},{"issue":"8279","key":"774_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(82)92016-5","volume":"1","author":"RA Joss","year":"1982","unstructured":"Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in cancer patient on high-dose domperidone. Lancet. 1982;1(8279):1019.","journal-title":"Lancet"},{"issue":"9","key":"774_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/pds.2016","volume":"19","author":"CB Johannes","year":"2010","unstructured":"Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881\u20138.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"774_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2165\/11536840-000000000-00000","volume":"33","author":"C van Noord","year":"2010","unstructured":"van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case\u2013control study in the Netherlands. Drug Saf. 2010;33(11):1003\u201314.","journal-title":"Drug Saf."},{"key":"774_CR15","unstructured":"European Medicines Agency\u2019s Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommends restricting use of domperidone. EMA\/129231\/2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/prac-recommends-restricting-use-domperidone_en.pdf. [Accessed 14 Nov 2019]."},{"key":"774_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.parkreldis.2019.04.012","volume":"64","author":"LL Mariani","year":"2019","unstructured":"Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carriere N, Danaila T, et al. Descriptive analysis of the French NS-Park registry: towards a nation-wide Parkinson\u2019s disease cohort? Parkinsonism Relat Disord. 2019;64:226\u201334.","journal-title":"Parkinsonism Relat Disord."},{"issue":"8","key":"774_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.parkreldis.2011.05.020","volume":"17","author":"AD Ha","year":"2011","unstructured":"Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson\u2019s disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011;17(8):625\u20138.","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"774_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","volume":"63","author":"JM Senard","year":"1997","unstructured":"Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, et al. Prevalence of orthostatic hypotension in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"10","key":"774_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.parkreldis.2011.04.016","volume":"17","author":"DC Velseboer","year":"2011","unstructured":"Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17(10):724\u20139.","journal-title":"Parkinsonism Relat Disord."},{"key":"774_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). Parkinson\u2019s disease in adults: diagnosis and management, full guideline. NICE guideline NG71, methods, evidence and recommendations. 2017 July."},{"issue":"5","key":"774_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/jnnp.65.5.709","volume":"65","author":"K Pietz","year":"1998","unstructured":"Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson\u2019s disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709\u201316.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"9","key":"774_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749\u201359.","journal-title":"Lancet Neurol."},{"issue":"11","key":"774_CR23","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1111\/bcp.13708","volume":"84","author":"M Simeonova","year":"2018","unstructured":"Simeonova M, de Vries F, Pouwels S, Driessen JHM, Leufkens HGM, Cadarette SM, et al. Increased risk of all-cause mortality associated with domperidone use in Parkinson\u2019s patients: a population-based cohort study in the UK. Br J Clin Pharmacol. 2018;84(11):2551\u201361.","journal-title":"Br J Clin Pharmacol."},{"issue":"11","key":"774_CR24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.parkreldis.2014.08.010","volume":"20","author":"RA Hauser","year":"2014","unstructured":"Hauser RA, Isaacson S, Clinch T. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014;20(11):1171\u20136.","journal-title":"Parkinsonism Relat Disord."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00774-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00774-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00774-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T11:08:38Z","timestamp":1608289718000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00774-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00774-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"4 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the ANSM (Agence National de S\u00e9curit\u00e9 du M\u00e9dicament). The \u201cDUMP\u201d is registered under reference EUPAS26319 and received an ENCePP Seal that recognizes studies following the ENCePP principles of standards, transparency, and independence.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. Competing financial interests unrelated to the present work: Louise-Laure Mariani received research support grants from INSERM, JNLF, and The L\u2019Oreal Foundation; received speech honoraria from CSL, Sanofi-Genzyme, Lundbeck, and Teva; was a consultant for Alzprotect, Bionure, and Digitsole; and received travel funding from the Movement Disorders Society, ANAINF, Merck, Merz, Medtronic, Teva, and AbbVie, outside the submitted work. Olivier Rascol served as a member of advisory boards for AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astrazeneca, Bial, Biogen, Britannia, Buckwang, Clevexel, INC Reasearch, Lundbeck, Lupin, Merck, MundiPharma, Neuratris, Neuroderm, Novartis, ONO Pharma, Orion Pharma, Osmotica, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Sunovion, Th\u00e9ranexus, Takeda, Teva, UCB, Watermark, Research, XenoPort, XO, and Zambon and received a grant from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJFox Foundation, Programme Hospitalier de Recherche Clinique, and the European Commission (FP7, H2020) as well as a grant to participate in a symposium and contribute to the review of an article IPMDS, outside the submitted work. Jean-Denis Turc received an honorarium from Abbvie for a symposium outside the submitted work. Jean-Christophe Corvol served as a member of advisory boards for UCB, Biogen, Prevail Therapeutic, Idorsia, Sanofi, Ever Pharma, Denali, BrainEver, and Theranexus, and received an unrestricted grant from the Michael J. Fox Foundation outside the present work. Florence Tubach is head of the Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi) of the Assistance Publique \u2013 H\u00f4pitaux de Paris and of the Clinical Research Unit of Piti\u00e9-Salp\u00eatri\u00e8re Hospital, both these structures have received research funding, grants, and fees for consultant activities from a large number of pharmaceutical companies that have contributed indiscriminately to the salaries of its employees. Florence Tubach did not receive any personal remuneration from these companies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an observational study that did not involve any patients. All data were collected anonymously. In accordance with French law, no ethical approval is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"L-LM, OR, J-DT, ML-M, J-CC, and FT contributed to the study conception and design. Analyses were performed by HA and DL. The first draft of the manuscript was written by DL and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}